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Abstract
Objectives To evaluate the risk of myocardial infarction and death from
coronary heart disease after discontinuation of low dose aspirin in primary
care patients with a history of cardiovascular events.
Design Nested case-control study.
Setting The Health Improvement Network (THIN) database in the United
Kingdom.
Participants Individuals aged 50-84 with a first prescription for aspirin
(75-300 mg/day) for secondary prevention of cardiovascular outcomes
in 2000-7 (n=39 513).
Main outcome measures Individuals were followed up for a mean of
3.2 years to identify cases of non-fatal myocardial infarction or death
from coronary heart disease. A nested case-control analysis assessed
the risk of these events in those who had stopped taking low dose aspirin
compared with those who had continued treatment.
Results There were 876 non-fatal myocardial infarctions and 346 deaths
from coronary heart disease. Compared with current users, people who
had recently stopped taking aspirin had a significantly increased risk of
non-fatal myocardial infarction or death from coronary heart disease
combined (rate ratio 1.43, 95% confidence interval 1.12 to 1.84) and
non-fatal myocardial infarction alone (1.63, 1.23 to 2.14). There was no
significant association between recently stopping low dose aspirin and
the risk of death from coronary heart disease (1.07, 0.67 to 1.69). For
every 1000 patients, over a period of one year there were about four
more cases of non-fatal myocardial infarction among patients who
discontinued treatment with low dose aspirin (recent discontinuers)
compared with patients who continued treatment.
Conclusions Individuals with a history of cardiovascular events who
stop taking low dose aspirin are at increased risk of non-fatal myocardial
infarction compared with those who continue treatment.
Introduction
Low dose regimens of the antiplatelet agent aspirin
(acetylsalicylic acid) are a standard treatment for the secondary
prevention of cardiovascular outcomes. Meta-analysis of
randomised controlled trials has shown that low dose aspirin is
protectiveinmosttypesofpatientatincreasedriskofocclusive
vascular events, including those who have had an acute
myocardial infarction or ischaemic stroke and those who have
stable or unstable angina, peripheral artery disease, or atrial
fibrillation.
1 Guidelines recommend long term use of low dose
aspirin(75-150mg/day)asaneffectiveantiplateletregimenfor
patients with cardiovascular disease, unless contraindicated.
2 3
Despite the strong evidence supporting the protective effects of
lowdoseaspirin,discontinuationratesofaround50%havebeen
reported in patients who have been taking this medication for
several years.
4 5 It is therefore of concern that recent
discontinuation has been linked to an increase in the risk of
ischaemic events and death. Cessation of treatment with oral
antiplatelet agents (including aspirin and thienopyridines) has
been shown to be an independent predictor of an increase in
mortality after acute coronary syndromes,
6 and multivariate
analysis has shown an increased risk of transient ischaemic
attackinthefourweeksafterdiscontinuationofaspirin.
7Another
study of a cohort of patients with acute coronary syndromes
foundthatacutecoronarysyndromeeventsoccurredonaverage
10daysafterdiscontinuationoflowdoseaspirin.
8Asystematic
review of the literature to date showed that withdrawal of low
dose aspirin is associated with a threefold increase in the risk
of adverse cardiovascular events.
9
All the studies on this topic to date, however, have taken place
in secondary care centres. We used a validated primary care
database to evaluate the risk of non-fatal myocardial infarction
and of death from coronary heart disease (both as separate end
points and as a combined measure) after discontinuation of low
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Research
RESEARCHdose aspirin in primary care patients taking it as secondary
prevention for cardiovascular disease.
Methods
Data source
The Health Improvement Network is a computerised medical
research database that contains systematically recorded data on
more than three million patients enrolled in primary care
practices in the United Kingdom. Almost all of the UK
population is registered with a primary care practitioner, and
the network is representative of the UK population with regard
to age, sex, and geographical distribution. It has also been
validated for use in pharmacoepidemiological research.
10
Participating primary care practitioners record data as part of
their routine care of patients, including demographic factors,
consultation rates, referrals, hospital admissions, results of
laboratory tests, diagnoses, and prescriptions written, and send
them to the network for use in research projects. The Read
classification is used to code specific diagnoses,
11 and a drug
dictionary based on data from the MULTILEX classification is
used to code drug prescriptions.
12
Studieshaveshownthat60-80%ofUKpatientswhotakeaspirin
for secondary prevention obtain their treatment by prescription
rather than over the counter.
13-15 This proportion increases with
age
13 and in those patients who do not have to pay prescription
charges.
15 The Health Improvement Network should therefore
be a representative source of data on low dose aspirin use in the
UK.
Source population
We used the network to identify individuals aged 50-84 with a
first ever prescription of low dose aspirin (defined as 75-300
mg/day) for the secondary prevention of cardiovascular or
cerebrovascular events (defined as a diagnosis of angina
(including stable angina), unstable angina, ischaemic heart
disease, myocardial infarction, cerebrovascular disease, stroke,
or transient ischaemic attack) from 1 January 2000 to 31
December 2007 (figure). Indications for first ever prescriptions
for low dose aspirin were identified from the patients’
computerised records. This was done manually when there was
more than one potential indication. Study participants were
required to have been registered with their primary care
practitioner for at least two years and to have a computerised
prescription history for at least a year before the start of the
study. They were also required to have no diagnosis of cancer,
alcohol abuse, or alcohol related disease.
All individuals in the study cohort were followed up from the
day after their first prescription of low dose aspirin (start date)
untilthefirstofthefollowingendpoints:firstrecordeddiagnosis
of myocardial infarction, cancer, alcohol abuse, age 85, death,
or the end of the study period (31 December 2007). The final
study cohort of 39 513 patients was followed up for a mean of
3.2 years (range 1.0 day to 8.0 years, SD 2.2).
Selection of cases and case validation
During follow-up, 3155 patients in the study cohort had a
recorded diagnosis of myocardial infarction (figure). We
manually reviewed the profiles of these patients, including the
free text comments, to ascertain the number of patients with a
new diagnosis of myocardial infarction or who died from
coronary heart disease. We excluded patients with myocardial
infarction if they were not admitted to hospital after the
ischaemic event (and patients who were admitted to an
emergencydepartmentanddischargedonthesameday)because
eventsthatdonotrequireadmissionhavelowerdiagnosticvalue
than those that do require admission, which results in greater
misclassification. Patients were also excluded if they were
admitted to hospital for any reason other than cardiovascular
disease and had a myocardial infarction while admitted.
Therewere2869recordeddeathsduringthefollow-up,and824
of these patients had a recorded cardiovascular diagnosis in the
30daysbeforedeath(figure).Wemanuallyreviewedtheprofiles
of these 824 individuals to identify those who had died from
coronary heart disease. All those with coronary heart disease
recorded on their death certificate as the underlying cause of
death, or who had had a recent coronary artery occlusion or
antemortem evidence of coronary heart disease in the absence
of another cause of death, were considered to have died from
coronary heart disease. All other patients were excluded.
Previous studies have found that validation of diagnoses of
myocardialinfarctionbyaprimarycarepractitionerandrecords
of death from coronary heart disease results in a confirmation
rate of more than 90%,
16 17 so we did not carry out further
validation with primary care practitioners in our study.
After the complete review process of patients with a diagnosis
of myocardial infarction and patients who had potentially died
from coronary heart disease, we classified 876 individuals as
having non-fatal myocardial infarction and 346 individuals as
having died from coronary heart disease (including fatal
myocardial infarction) (figure).
Selection of controls
From the same source population of 39 513 patients, we
randomly sampled a control group of 5000 individuals,
frequency matched to the cases by age, sex, and calendar year.
We used incidence density sampling so that the likelihood of
being selected as a control was proportional to the person time
at risk. To do this, we generated a date at random during the
study period for each of the members of the source population.
We obtained the random date with a pseudo-random number
generator included in the C++ standard library. If the random
dateofastudymemberwasincludedinhisorhereligibleperson
time, we used his or her random date as the index date and
marked that person as an eligible control.
Assessment of risk factors
From the database we collected data on potential risk factors,
including the number of visits to a primary care practitioner,
referrals, and admissions to hospital (the year before the index
date), lifestyle factors (any time before the index date),
morbidities (any time before the start date), and drug treatment
(betweenthestartdateandtheindexdate).Drugtreatmentother
than low dose aspirin was classified into four categories:
• current use—when the supply of the most recent
prescription lasted until the index date or ended in the six
days before the index date
• recentuse—whenthesupplyofthemostrecentprescription
ended seven to 90 days before the index date (for all
medications, except warfarin, for which recent use was
defined as seven to 365 days before the index date)
• past use—when the most recent prescription ended 91 to
365 days before the index date
• non-use—when there was no recorded use of the relevant
drug in the 365 days before the index date.
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patients who did not completely adhere to their treatment and
might still have been using the drug after the specified
completion date.
Assessment of discontinuation of low dose
aspirin
Current users were defined as individuals who were taking low
dose aspirin at the index date, and discontinuers were defined
as individuals with a period of over 30 days after the last
prescription would have been finished (assuming complete
adherence)whodidnotrefilltheirprescriptionduringthistime.
Discontinuerswerethencategorisedintotwomutuallyexclusive
groups:
• recent discontinuers were patients whose last prescription
for low dose aspirin finished 31 to 180 days before the
index date
• distant discontinuers were those whose last prescription
finished 181 to 365 days before the index date.
To assess the effect of the definition of discontinuation, we
performed a second analysis with discontinuation defined as a
period of over 15 days after the last prescription would have
been finished (assuming complete adherence), with no refill of
the prescription during this time. In each case, investigators
were blinded as to whether the record belonged to a case or a
control.
Weidentifiedreasonsfordiscontinuationthroughmanualreview
of patients’ profiles and classified them into four mutually
exclusive categories:
• treatment change—defined as a switch, initiated by a
physician, from low dose aspirin to another antiplatelet
drug (such as clopidogrel or dipyridamole) or to an
anticoagulantsuchaswarfarin,withnoevidencetosuggest
an adverse event related to aspirin
• safety concerns—defined as evidence of an adverse event
related to low dose aspirin treatment (such as upper
gastrointestinal bleeding or other upper gastrointestinal
complications), intolerance to low dose aspirin
(allergy/urticaria),initiationofgastroprotectivemedication,
or planned surgery
• useofoverthecounteraspirin—reportedwhenthegeneral
practitioner specified that patients were taking low dose
aspirinintheabsenceofarecordedprescriptionforaspirin
• non-adherence—definedasdiscontinuationintheabsence
of any of the above factors.
Analysis
We calculated the incidence of non-fatal myocardial infarction
andofdeathfromcoronaryheartdiseaseandperformedanested
case-control analysis using unconditional logistic regression to
assess potential risk factors for these outcomes.
18 The logistic
regressionwasusedtoestimateoddsratios,whichareunbiased
estimatesofincidencerateratiosinincidencedensitysampling.
19
The analyses used the occurrence of myocardial infarction and
deathfromcoronaryheartdiseaseasthedependentvariableand
the factors listed below as independent variables. Missing
demographic data were assessed as a separate category. Risk
estimateswereadjustedbyage,sex,calendaryear,timetoevent,
smoking status, ischaemic heart disease (at start date),
cerebrovascular disease (at start date), diabetes (at start date),
chronic obstructive pulmonary disease (at start date), and use
ofclopidogrel,statins,anticoagulants,nitrates,antihypertensives,
oralsteroids,ornon-steroidalanti-inflammatorydrugs.Analyses
werestratifiedbysexandage.Thesignificanceoftheinteraction
was tested with a likelihood test ratio by comparing a model
with the main effect of two variables (sex and discontinuation)
and the interaction term with a reduced model incorporating
only the main effects. We also performed sensitivity analyses
to assess the risk of residual confounding.
Results
Incidence of non-fatal myocardial infarction
and death from coronary heart disease
Over a mean follow-up of 3.2 years, we identified 876
individuals with a new diagnosis of non-fatal myocardial
infarction (figure). In addition, we identified 346 individuals as
having died from coronary heart disease. The overall incidence
of non-fatal myocardial infarction was 6.87 per 1000 person
years (95% confidence interval 6.43 to 7.34). The overall
incidence of death from coronary heart disease was 2.71 per
1000 person years (2.44 to 3.02). The incidence of these
outcomes stratified by indication for low dose aspirin is shown
in table B in the appendix on bmj.com.
The combined incidence of non-fatal myocardial infarction or
death from coronary heart disease was 9.58 per 1000 person
years (9.06 to 10.14). This was higher in the first year of
follow-up (12.92 per 1000 person years, 11.78 to 14.17) than
in the rest of the study period (8.33, 7.76 to 8.94).
Risk factors for non-fatal myocardial
infarction and death from coronary heart
disease
Several baseline characteristics and lifestyle factors were
associated with a significantly increased risk of non-fatal
myocardial infarction or death from coronary heart disease in
users of low dose aspirin (table 1). Current smokers had a
significantly increased risk of non-fatal myocardial infarction
or death from coronary heart disease compared with
non-smokers, and patients who had been admitted to hospital
in the year before the index date had a significantly greater risk
than those who had not been admitted in that time. Compared
withnodiagnosisoftherespectivedisease,apreviousdiagnosis
of chronic obstructive pulmonary disease or diabetes was also
associated with a significant increase in the risk of non-fatal
myocardial infarction or death from coronary heart disease in
this cohort of patients taking low dose aspirin (table 1).
Concomitantuseoforalsteroids(rateratio2.32,95%confidence
interval 1.65 to 3.26) and traditional non-steroidal
anti-inflammatory drugs (1.36, 1.04 to 1.77) was associated
with a significant increase in the risk of non-fatal myocardial
infarction or death from coronary heart disease compared with
non-use. In contrast, patients currently taking statins had a
significantdecreaseinriskcomparedwithnon-users(0.82,0.69
to 0.97).
Discontinuation of low dose aspirin and
cardiovascular outcomes
Among the 1222 cases, 877 (72%) were still using low dose
aspirin, 108 (9%) were recent discontinuers, and 41 (3%) were
distant discontinuers. Among the 5000 controls, 3784 (76%)
were still using low dose aspirin, 357 (7%) were recent
discontinuers, and 195 (4%) were distant discontinuers. Most
recent discontinuers were non-adherent (68% of all recent
discontinuers). Twelve per cent of patients switched to another
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the counter low dose aspirin.
Individualswhohadrecentlydiscontinuedlowdoseaspirinhad
asignificantlyincreasedriskofnon-fatalmyocardialinfarction
or death from coronary heart disease compared with current
users (rate ratio 1.43, 1.12 to 1.84; table 2). This increased risk
among recent discontinuers was similar for different durations
of treatment with aspirin (table 2), and for the different
indications (data not shown). There was no significant
association between distant discontinuation of low dose aspirin
and the risk of non-fatal myocardial infarction or death from
coronary heart disease (1.19, 0.82 to 1.71) compared with
current low dose aspirin use. There was also no significant
difference in risk in distant discontinuers compared with recent
discontinuers(datanotshown).Theincreaseinriskwasvirtually
unchanged when we changed the definition of recent
discontinuation to a period of more than 15 days after the end
of the last prescription for low dose aspirin (1.41, 1.12 to 1.76).
The risk estimate was also similar when we further adjusted the
multivariate model by the number of admissions to hospital in
the year before the index date (1.46, 1.14 to 1.87).
When we categorised recent discontinuers according to their
reason for discontinuation, there was a significant increase in
the risk of myocardial infarction or death from coronary heart
disease in those who were non-adherent (rate ratio 1.54 (1.15
to 2.06) compared with current use), but not in those who were
defined as discontinuers but who were subsequently found to
betakingoverthecounterlowdoseaspirin(rateratio0.82(0.28
to 2.38) compared with current use).
Recent discontinuers of low dose aspirin had a significantly
increasedriskofnon-fatalmyocardialinfarctioncomparedwith
current users (rate ratio 1.63, 1.23 to 2.14; table 3). Based on
an incidence of non-fatal myocardial infarction of about six per
1000 person years among current users of low dose aspirin, the
incidence among recent discontinuers can be estimated as 10
per 1000 patient years: an extra four cases of non-fatal
myocardial infarction associated with discontinuation among
1000 aspirin users. The risk of non-fatal myocardial infarction
was significantly increased in patients who did not adhere to
treatmentbutnotinthosewhoweretakingoverthecounterlow
doseaspirin(table3).Theriskofnon-fatalmyocardialinfarction
in recent discontinuers varied slightly across the different age
groups (table 3). The risk was higher in women than in men,
but this difference was not significant (P=0.16 for interaction).
There was no significant association between discontinuation
of low dose aspirin treatment and death from coronary heart
diseaseamongrecentdiscontinuers(rateratio1.07,0.67to1.69)
or distant discontinuers (1.02, 0.54 to 1.94) compared with
current users. There was also no significant increase in the risk
of death from coronary heart disease when recent discontinuers
were restricted to those who were truly non-adherent (rate ratio
1.03, 0.59 to 1.79).
The risk of myocardial infarction or death from coronary heart
disease seemed to be unaffected by adherence to other
medications.Forexample,theriskinpatientswhodiscontinued
low dose aspirin but were adherent to antihypertensive drugs
(rate ratio 1.54, 1.00 to 2.38) was similar to that in the overall
cohort. Similarly, there was no significant increase in the risk
inpatientswhodiscontinuedotherdrugs(seetableCinappendix
on bmj.com). Sensitivity analyses showed the association
between discontinuing low dose aspirin and the risk of
myocardial infarction or death from coronary heart disease to
be robust. For the increased risk of coronary events among
recent discontinuers to become non-significant, the analysis
would have to be adjusted by an unknown confounder with an
overall prevalence of 25% that is twice as common among
discontinuersthannon-discontinuersandamajorriskfactorfor
coronary events (rate ratio of ≥3).
Discussion
Patients with a history of cardiovascular or cerebrovascular
disease in primary care who stop taking low dose aspirin are at
asignificantlyincreasedriskofnon-fatalmyocardialinfarction
compared with those who continue such treatment. The
increased risk is present irrespective of the length of time the
patient had previously been taking low dose aspirin. This
supports the results of previous studies in secondary care
6 8 and
shows that they are applicable to the general population. An
additional important finding is that the cumulative incidence of
non-fatal myocardial infarction or death from coronary heart
disease in patients taking low dose aspirin after a myocardial
infarction was 4% during the mean follow-up of three years.
This is consistent with data from clinical trials on the
effectiveness of antithrombotic treatment for the secondary
prevention of cardiovascular events, which indicate that 2-14%
of patients (followed for a mean of 1 to 41 months) have a
subsequent ischaemic event.
20-23
Strengths and weaknesses
A major strength of this study is that use of The Health
ImprovementNetworkenabledanalysisofanextensivesample
that was representative of the UK primary care population and
had age and sex distributions similar to those in the national
population. Also, the network includes all patients in
participating practices who have been diagnosed as having a
primary cardiovascular event and prescribed low dose aspirin
to prevent a secondary event in primary care, supporting the
broadexternalvalidityofthesefindings.Moreover,weobserved
the increased risk of non-fatal myocardial infarction in patients
who were truly non-adherent but not in those who were found
to be taking over the counter aspirin, which reinforces the
internal validity of this study.
A potential limitation of the study is that use of aspirin might
have been misclassified in some cases. For example, the
recording of a prescription for low dose aspirin in The Health
ImprovementNetworkdoesnotnecessarilymeanthatthepatient
actually took it, although it is likely that many did as there was
a prescription almost every month for most patients. Lack of
systematic recording of over the counter aspirin is another
potential source of misclassification. As described above,
however, in the age range studied use of low dose aspirin for
secondary prevention is predominantly prescription based.
13 15
Another limitation is the potential for confounding, which is a
limitation of all observational studies. We have tried to control
for this as much as possible by adjusting the multivariate
analysesbydemographicfactors,traditionalcardiovascularrisk
factors, comorbidity, and drug use. Nevertheless, it is not
possible to control for all possible confounding factors, and it
should be acknowledged that some of these factors might have
had an impact on aspirin discontinuation rates. Sensitivity
analyses showed that the association between discontinuation
and the risk of myocardial infarction or death from coronary
heart disease was robust. We think that it would therefore be
unlikely for the association to be explained by unmeasured
confounding.
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RESEARCHConclusions and clinical implications
We have shown that discontinuation of low dose aspirin
increases the risk of non-fatal myocardial infarction in patients
with a history of ischaemic events in primary care. The
magnitudeofthisshorttermincreaseinriskafterdiscontinuation
isabouttheinverseofthebenefitobtainedwithuseoflowdose
aspirintreatmentforsecondaryprevention.Theimplicationsof
interrupting such treatment should be taken into account when
managing the secondary prevention of cardiovascular events in
primary care.
Non-adherence in patients was the most common reason for
discontinuation of low dose aspirin. Additional research is
required to determine why patients stop this treatment in the
absence of a clinical reason. Patients might not adhere to
treatment because they forget to take it, because they do not
perceive that it has therapeutic benefit, or because of adverse
events not discussed with their primary care practitioner.
Recordedsafetyconcernswerethesecondmostcommonreason
for discontinuation in this study. Upper gastrointestinal side
effects, including peptic ulcer disease and bleeding,
24 25 are the
most serious adverse effects related to aspirin use.
26 Low dose
aspirin, however, is of substantial net benefit in secondary
prevention because the reduction in the risk of major coronary
events outweighs the increased risk of major gastrointestinal
bleeding in patients at high risk of cardiovascular events.
1 22 23 27
Reducing the number of patients who discontinue low dose
aspirin could therefore have a major impact on the benefit
obtained with low dose aspirin in the general population.
Researchisnowneededtoevaluatewhethereffortstoencourage
patientstocontinueprophylactictreatmentwithlowdoseaspirin
will result in a decrease in non-fatal myocardial infarction.
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RESEARCHWhat is already known on this topic
Low dose aspirin is standard treatment for the secondary prevention of cardiovascular disease, though up to half of
long term users stop taking it
Secondary care studies have shown that discontinuation is associated with an increased risk of ischaemic events and
death
What this study adds
Discontinuation of low dose aspirin increases the risk of non-fatal myocardial infarction or death from coronary heart
disease by almost 50% in patients in primary care who have a history of ischaemic events
There is no increase in the risk of death from coronary heart disease alone in patients who discontinue low dose aspirin
The increased risk of non-fatal myocardial infarction after discontinuation is present irrespective of the length of time
the patient had previously been taking low dose aspirin.
Research is now needed to test whether efforts to encourage patients to continue prophylactic treatment with low dose
aspirin result in a decrease in non-fatal myocardial infarction
Tables
Table 1| Rate ratios for combined non-fatal myocardial infarction (MI) or death from coronary heart disease (CHD) associated with various
factors in patients taking low dose aspirin
Rate ratio (95% CI)
No (%) with non-fatal
MI/CHD death (n=1222) No (%) of controls (n=5000) Factor Adjusted† Unadjusted*
Smoking:
1.00 1.00 404 (33.1) 2014 (40.3) Never
1.67 (1.38 to 2.03) 1.86 (1.55 to 2.23) 259 (21.2) 724 (14.5) Current
1.15 (0.98 to 1.35) 1.28 (1.10 to 1.48) 527 (43.1) 2135 (42.7) Former
1.26 (0.82 to 1.91) 1.08 (0.72 to 1.63) 32 (2.6) 127 (2.5) Unknown
BMI:
1.04 (0.69 to 1.58) 1.16 (0.78 to 1.73) 35 (2.9) 133 (2.7) 15-19
1.00 1.00 304 (24.9) 1316 (26.3) 20-24
1.10 (0.93 to 1.31) 1.06 (0.90 to 1.24) 469 (38.4) 1934 (38.7) 25-29
1.10 (0.91 to 1.34) 1.16 (0.96 to 1.39) 284 (23.2) 1119 (22.4) 30-59
1.13 (0.87 to 1.46) 1.07 (0.85 to 1.35) 130 (10.6) 498 (10.0) Unknown
Visits to primary care practitioner‡:
1.00 1.00 86 (7.0) 441 (8.8) <5
0.98 (0.74 to 1.30) 1.02 (0.78 to 1.33) 255 (20.9) 1356 (27.1) 5-9
1.16 (0.89 to 1.53) 1.35 (1.05 to 1.74) 518 (42.4) 2147 (42.9) 10-19
1.49 (1.11 to 2.00) 1.96 (1.50 to 2.55) 363 (29.7) 1056 (21.1) ≥20
Referrals‡:
1.00 1.00 472 (38.6) 2391 (47.8) 0-1
1.22 (1.04 to 1.44) 1.34 (1.15 to 1.56) 379 (31.0) 1476 (29.5) 2-4
1.39 (1.15 to 1.68) 1.65 (1.39 to 1.97) 249 (20.4) 812 (16.2) 5-9
1.71 (1.32 to 2.20) 2.10 (1.66 to 2.66) 122 (10.0) 321 (6.4) ≥10
Admission to hospital‡:
1.00 1.00 834 (68.3) 4133 (82.7) 0
1.76 (1.49 to 2.08) 2.11 (1.81 to 2.46) 309 (25.3) 721 (14.4) 1-2
2.06 (1.50 to 2.83) 2.74 (2.06 to 3.65) 79 (6.5) 146 (2.9) ≥3
Morbidity at start date§:
1.91 (1.61 to 2.55) 1.95 (1.70 to 2.23) 450 (36.8) 1160 (23.2) Myocardial infarction
1.10 (0.93 to 1.30) 1.19 (1.04 to 1.35) 491 (40.2) 1790 (35.8) Angina
1.43 (1.04 to 1.96) 1.69 (1.26 to 2.27) 66 (5.4) 162 (3.2) Unstable angina
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RESEARCHTable 1 (continued)
Rate ratio (95% CI)
No (%) with non-fatal
MI/CHD death (n=1222) No (%) of controls (n=5000) Factor Adjusted† Unadjusted*
1.24 (1.04 to 1.49) 0.72 (0.63 to 0.83) 334 (27.3) 1704 (34.1) Cerebrovascular disease
1.56 (1.22 to 1.99) 2.04 (1.65 to 2.54) 137 (11.2) 286 (5.7) COPD
1.49 (1.24 to 1.78) 1.48 (1.25 to 1.75) 218 (17.8) 645 (12.9) Diabetes
1.04 (0.78 to 1.41) 0.98 (0.75 to 1.27) 73 (6.0) 294 (5.9) Atrial fibrillation
BMI=body mass index; COPD=chronic obstructive pulmonary disease.
*Adjusted for matched variables: sex, age, and calendar year.
†Adjusted for age, sex, calendar year, time to event, smoking, ischaemic heart disease (at start date), cerebrovascular disease (at start date), diabetes (at start
date), COPD (at start date), atrial fibrillation (at start date), use of clopidogrel, statins, anticoagulants, nitrates, antihypertensives, oral steroids or non-steroidal
anti-inflammatory drugs, and discontinuation of aspirin.
‡In year before index date.
§Reference group: no diagnosis of relevant morbidity.
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RESEARCHTable 2| Risk of non-fatal myocardial infarction (MI) or death from coronary heart disease (CHD) among recent discontinuers of low dose
aspirin
Rate ratio (95% CI)
No (%) with non-fatal
MI/CHD death (n=1222)
No (%) of controls
(n=5000) Adjusted† Unadjusted*
1.00 1.00 877 (71.8) 3784 (75.7) Current users
1.43 (1.12 to 1.84) 1.30 (1.04 to 1.63) 108 (8.8) 357 (7.1) Recent discontinuers
Duration of treatment:
1.42 (1.08 to 1.85) 1.31 (1.02 to 1.67) 92 (7.5) 302 (6.0) ≤1 year
1.45 (0.87 to 2.44) 1.51 (0.93 to 2.45) 23 (1.9) 65 (1.3) ≤30 days
1.41 (1.05 to 1.91) 1.25 (0.95 to 1.66) 69 (5.6) 237 (4.7) 31-365 days
1.48 (0.82 to 2.69) 1.26 (0.72 to 2.22) 16 (1.3) 55 (1.1) >1 year
Daily dose:
1.40 (1.08 to 1.81) 1.27 (1.00 to 1.61) 98 (8.0) 333 (6.7) ≤75 mg
1.94 (0.89 to 4.22) 1.79 (0.85 to 3.77) 10 (0.8) 24 (0.5) 75-300 mg
Reason for discontinuation:
1.54 (1.15 to 2.06) 1.32 (1.01 to 1.73) 75 (6.1) 242 (4.8) Lack of adherence
1.94 (1.01 to 3.74) 1.95 (1.09 to 3.46) 17 (1.4) 39 (0.8) Treatment change
0.97 (0.50 to 1.91) 1.04 (0.55 to 1.97) 12 (1.0) 49 (1.0) Safety concerns
0.82 (0.28 to 2.38) 0.68 (0.24 to 1.94) 4 (0.3) 27 (0.5) Use of over the counter aspirin
Stratified by age (years)
— — 286 1242 No aged <65
1.73 (1.04 to 2.87) 1.37 (0.87 to 2.15) 28 (9.8) 91 (7.3) Recent discontinuers
— — 393 1751 No aged 65-74
1.32 (0.84 to 2.05) 1.23 (0.82 to 1.85) 33 (8.4) 127 (7.3) Recent discontinuers
— — 543 2007 No aged ≥75
1.39 (0.95 to 2.05) 1.32 (0.93 to 1.87) 47 (8.7) 139 (6.9) Recent discontinuers
Stratified by sex
— — 810 3198 No of men
1.28 (0.94 to 1.76) 1.25 (0.94 to 1.67) 68 (8.4) 225 (7.0) Recent discontinuers
— — 412 1802 No of women
1.71 (1.13 to 2.58) 1.38 (0.95 to 2.01) 40 (9.7) 132 (7.3) Recent discontinuers
*Adjusted for matched variables: sex, age, and calendar year.
†Adjusted for age, sex, calendar year, time to event, smoking status, ischaemic heart disease (at start date), cerebrovascular disease (at start date), diabetes (at
start date), chronic obstructive pulmonary disease (at start date), and use of clopidogrel, statins, anticoagulants, nitrates, antihypertensives, oral steroids, or
non-steroidal anti-inflammatory drugs.
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RESEARCHTable 3| Risk of non-fatal myocardial infarction (MI) in recent discontinuers of low dose aspirin
Rate ratio (95% CI)
No (%) with non-fatal MI
(n=876)
No (%) of controls
(n=5000) Adjusted† Unadjusted*
1.00 1.00 622 (71.0) 3784 (75.7) Current users
1.63 (1.23 to 2.14) 1.40 (1.08 to 1.80) 82 (9.4) 357 (7.1) Recent discontinuers
Treatment duration:
1.62 (1.21 to 2.18) 1.42 (1.08 to 1.87) 71 (8.1) 302 (6.0) ≤1 year
1.39 (0.76 to 2.55) 1.39 (0.79 to 2.46) 15 (1.7) 65 (1.3) ≤30 days
1.70 (1.23 to 2.36) 1.43 (1.06 to 1.94) 56 (6.4) 237 (4.7) 31-365 days
1.62 (0.82 to 3.22) 1.23 (0.64 to 2.37) 11 (1.3) 55 (1.1) >1 year
Daily dose:
1.59 (1.19 to 2.12) 1.37 (1.05 to 1.79) 75 (8.6) 333 (6.7) ≤75 mg
2.14 (0.88 to 5.17) 1.74 (0.74 to 4.06) 7 (0.8) 24 (0.5) 76-300 mg
Reason for discontinuation:
1.80 (1.31 to 2.48) 1.48 (1.10 to 1.99) 59 (6.7) 242 (4.8) Lack of adherence
2.19 (1.04 to 4.60) 1.89 (0.98 to 3.63) 12 (1.4) 39 (0.8) Treatment change
0.93 (0.42 to 2.05) 0.99 (0.46 to 2.10) 8 (0.9) 49 (1.0) Safety concerns
0.86 (0.25 to 2.89) 0.68 (0.21 to 2.27) 3 (0.3) 27 (0.5) Use of over the counter aspirin
Stratified by age (years)
— — 227 1242 No aged <65
1.56 (0.89 to 2.76) 1.33 (0.80 to 2.20) 21 (9.3) 91 (7.3) Recent discontinuers
— — 310 1751 No aged 65-74
1.34 (0.82 to 2.19) 1.23 (0.79 to 1.92) 26 (8.4) 127 (7.3) Recent discontinuers
— — 339 2007 No aged ≥75
1.96 (1.27 to 3.02) 1.60 (1.08 to 2.38) 35 (10.3) 139 (6.9) Recent discontinuers
Stratified by sex
— — 566 3198 No of men
1.36 (0.95 to 1.95) 1.29 (0.93 to 1.79) 48 (8.5) 225 (7.0) Recent discontinuers
— — 310 1802 No of women
2.14 (1.38 to 3.33) 1.58 (1.05 to 2.37) 34 (11.0) 132 (7.3) Recent discontinuers
*Adjusted for matched variables: sex, age, and calendar year.
†Adjusted for age, sex, calendar year, time to event, smoking status, ischaemic heart disease (at start date), cerebrovascular disease (at start date), diabetes (at
start date), chronic obstructive pulmonary disease (at start date), and use of clopidogrel, statins, anticoagulants, nitrates, antihypertensives, oral steroids, or
non-steroidal anti-inflammatory drugs.
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RESEARCHFigure
Study design and case ascertainment of non-fatal myocardial infarction and death from coronary heart disease among
people prescribed aspirin in primary care
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